BAY 1834845

Drug Profile

BAY 1834845

Alternative Names: BAY 1834845

Latest Information Update: 07 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bayer
  • Class Anti-inflammatories
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pelvic inflammatory disorders

Most Recent Events

  • 07 Aug 2017 Bayer plans a phase I trial of BAY1834845 for Inflammation (In volunteers) in August 2017 (PO) (IV) (NCT03244462)
  • 01 Feb 2017 Phase-I clinical trials in Pelvic inflammatory disorders (In volunteers) in Germany (PO, Liquid)
  • 01 Feb 2017 Phase-I clinical trials in Pelvic inflammatory disorders (In volunteers) in Germany (PO, Tablet) (NCT03054402)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top